Balaxi Pharmaceuticals Limited (NSE:BALAXI)

Balaxi Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	145.59	394	622.91	282.17	71.93
Short-Term Investments	-	13.04	2.81	2.48	1.84
Cash & Short-Term Investments	145.59	407.03	625.72	284.65	73.77
Cash Growth	-64.23%	-34.95%	119.82%	285.85%	342.01%
Accounts Receivable	1,361	1,108	557.05	522.82	275.59
Other Receivables	-	18.66	12.95	10.73	18.48
Receivables	1,365	1,158	589.01	550.02	311.84
Inventory	834.8	784.81	821.68	1,050	987.04
Prepaid Expenses	-	22.14	20.17	37.77	31.22
Other Current Assets	168.56	55.99	45.14	12.44	6.16
Total Current Assets	2,514	2,428	2,102	1,935	1,410
Property, Plant & Equipment	490.11	363.11	170.87	190.16	60.27
Long-Term Investments	-	-	-	-	44.7
Goodwill	326.71	267.45	261	252.24	233.02
Other Long-Term Assets	39.18	45.21	49.84	19.19	16.69
Total Assets	3,370	3,103	2,583	2,397	1,765

Liabilities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	212.08	161.78	290.38	345.19	491.15
Accrued Expenses	-	46.02	46.1	28.02	32.6
Short-Term Debt	334.37	303.8	176.61	107.51	36.38
Current Income Taxes Payable	-	33.67	28.83	50.57	72.52
Other Current Liabilities	75.13	0.05	0.05	0.05	0.03
Total Current Liabilities	621.58	545.32	541.98	531.33	632.68
Long-Term Debt	223.53	212.45	-	8.7	-
Long-Term Leases	18.59	18.01	17.43	16.86	-
Long-Term Deferred Tax Liabilities	13.35	9	9.95	11.01	0.39
Other Long-Term Liabilities	2.49	1.29	0.43	-	-
Total Liabilities	879.53	786.06	569.79	567.89	633.06

Shareholders' Equity

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	110.42	110.42	108.98	101.81	100
Additional Paid-In Capital	-	565.8	508.44	192.46	112.53
Retained Earnings	-	1,641	1,358	1,432	919.11
Comprehensive Income & Other	2,380	-	37.73	102.97	-
Shareholders' Equity	2,491	2,317	2,014	1,829	1,132
Total Liabilities & Equity	3,370	3,103	2,583	2,397	1,765

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	576.49	534.25	194.04	133.07	36.38
Net Cash (Debt)	-430.9	-127.22	431.68	151.58	37.39
Net Cash Growth	-	-	184.78%	305.40%	-
Net Cash Per Share	-7.91	-2.30	8.39	2.99	0.75
Filing Date Shares Outstanding	55.71	55.21	50.91	50.91	50
Total Common Shares Outstanding	55.71	55.21	50.91	50.91	50
Working Capital	1,893	1,882	1,560	1,404	777.36
Book Value Per Share	44.71	41.98	39.56	35.92	22.63
Tangible Book Value	2,164	2,050	1,753	1,577	898.62
Tangible Book Value Per Share	38.85	37.13	34.43	30.97	17.97

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 28, 2026

Data Sources Report a data error